Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Francesca Mancini

Guido Furlotti

Nicola Cazzolla

Maria Alessandra Alisi

Rosella Ombrato

Antonio Vicente Ferrer Montiel

Giorgina Mangano

Barbara Garofalo

Caterina Maugeri

Patrizia Dragone

Gregorio Fernández Ballester

Isabel Devesa Giner

Cristina Bartella

Gabriele Magaro'

Gabriele Magaro′

The invention relates to peptides capable of inhibiting neuronal exocytosis and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions, disorders and/or diseases mediated by neuronal exocytosis, such as wrinkles, excessive perspiration, pruritus, cutaneous inflammation, dermatitis, atopia, psoriasis, vascular hyperreactivity, rosacea, acne, hair growth, wound healing, calluses, warts, or sensitive skin conditions, such as ulcers and lesions on the skin.

Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof

Peptides able to inhibit the muscarinic receptor M3 activity and to products comprising such peptides, in particular pharmaceutical and cosmetic products useful for ameliorating skin conditions mediated by the muscarinic receptor M3 activity, such as excessive perspiration, inflammation, sebum production, and cell adhesion, motility, growth, differentiation and proliferation.

Peptides having inhibitory activity on muscarinic receptor M3

The present invention relates to the 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.

Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

The present invention relates to the 1H-indazole-3-carboxamide compounds having the following general formula (I) as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3p-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain. 

1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors. The present invention relates to the 1H-indazole-3-carboxamide compounds for use as glycogen synthase kinase 3 beta (GSK-3&#x3b2;) inhibitors and to their use in the treatment of GSK-3&#x3b2;-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies. 

Growing community of inventors

Nettuno, Italy

Francesca Mancini